Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

*
(*) mandatory field





 

Other search option(s)

Neuroectodermal melanolysosomal disease

Orpha number ORPHA33445
Synonym(s) Elejalde disease
Elejalde syndrome
Prevalence <1 / 1 000 000
Inheritance -
Age of onset Childhood
ICD-10 -
OMIM
UMLS
  • C1860157
MeSH
  • C536203
MedDRA -
SNOMED CT -

Summary

Elejalde syndrome (ES) is characterized by silvery to leaden hair, bronze skin colour in sun-exposed areas and severe neurological impairment. The syndrome was first described in 1979 in three consanguineous families. To date, about 20 patients have been reported in the literature. It is either congenital or develops during childhood (seizures, severe hypotonia and intellectual deficit). There is no impairment of the immune system and a wide spectrum of ophthalmologic abnormalities has been described. ES hair samples show irregular clumps of melanin under the microscope and skin melanocytes contain many irregularly shaped melanosomes with an incomplete transfer-block towards surrounding keratinocytes. Ultrastructurally, abnormal inclusion bodies are observed in fibroblasts, bone marrow histiocytes and lymphocytes. The etiology of ES is still unknown, but recent molecular data have shed light on the complex relationship that exists between ES and the Griscelli syndrome (see this term). Mutations in the myosin Va gene (MYOVA) result in the so-called Griscelli syndrome type 1, characterized by cutaneous and neurologic manifestations. MYOVA encodes myosin Va, an actin-based motor protein important for the intracellular transport of organelles in melanocyte and neuronal cells. It is very likely that Griscelli syndrome type 1 corresponds to ES. The main differential diagnoses are Griscelli syndrome type 2 (caused by mutations in RAB27A), which is characterized by cutaneous and immunological manifestations, without primary neurological signs; Griscelli syndrome type 3, which has only cutaneous hypopigmentation as a feature and is caused by mutations in MLPH; and Chediak-Higashi syndrome (see this term), also characterized by silvery hair, and by oculocutaneous hypopigmentation. It can lead to death by infection and/or lymphoma-like organ infiltration (so-called accelerated phases), and is caused by mutations in the LYST gene. Treatment for ES remains limited: corticosteroids, anticonvulsants and antipyretics fail to prevent early death from severe neurologic dysfunction.

Expert reviewer(s)

  • Pr Jean-Marie NAEYAERT

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.


Captcha image
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.